Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITM-23
- Development stage
- Unknown
- Lead developer
- ITM Isotope Technologies Munich
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ITM-23 is a targeted radiopharmaceutical developed by Isotope Technologies Garching (ITM) for the treatment of prostate cancer. It consists of a ligand that specifically targets the Prostate-Specific Membrane Antigen (PSMA), which is highly expressed on the surface of prostate cancer cells, including metastatic lesions. The ligand is conjugated to Terbium-161 (Tb-161), a radioisotope that emits both beta particles and a high density of Auger and conversion electrons. This dual emission profile allows for effective cell killing through DNA damage, particularly in small tumor clusters and micrometastases, while minimizing damage to adjacent healthy tissues. ITM-23 is currently in Phase 1 clinical development for patients with prostate cancer.
- Other names
- Tb-161-PSMATb161-PSMATb 161-PSMATerbium-161-PSMATerbium161-PSMATerbium 161-PSMA
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on ITM-23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITM-23.